BrightFocus-Funded Research Shows Parkinson’s Drug Could be Repurposed to Save Sight of Millions
In a major scientific breakthrough, a drug used to treat Parkinson’s and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.
The findings, published in the American Journal of Medicine, are a groundbreaking effort in the fight against age-related macular degeneration (AMD), which affects as many as 11 million Americans. AMD hinders central vision, and even when it does not lead to blindness it can severely reduce the ability to read, drive, and recognize faces.
In the study, supported in part by BrightFocus Foundation, researchers discovered a biological connection between darker pigmented eyes, that are known to be resistant to AMD, and increased levels of a chemical called L-DOPA in those eyes. Since L-DOPA is frequently prescribed for Parkinson’s patients, the researchers wanted to know whether patients who received the drug L-DOPA as treatment for Parkinson’s or other diseases were protected from AMD. By combing through massive databases of medical chart data, they reported that patients receiving L-DOPA were significantly less likely to get AMD, and when they did, its onset was significantly delayed.
“Rather than looking at what might cause AMD, we instead wondered why certain people are protected from AMD. This approach had never been done before,” says senior author Brian McKay of the University of Arizona.
The research findings are based off an analysis of the medical records of 37,000 patients at the Marshfield Clinic in Wisconsin. Because the average age of those given L-DOPA is 67, while the average age of AMD diagnosis is 71, scientists were able to effectively track patterns. These major findings were then confirmed by reviewing a data set of 87 million patients. In this large scale data set, L-DOPA also delayed or prevented AMD from progressing to its “wet” form, the most devastating form of the disease.
“This exciting breakthrough shows the power of scientific discovery to give hope to millions of people across the nation and the world. Their methodology is a reminder that ‘big data’ is not a buzzword—it is a bold and innovative new approach to science,” said BrightFocus president and CEO Stacy Pagos Haller.
The Latest on: L-DOPA
via Google News
The Latest on: L-DOPA
- Emily Balskus wins $1M Waterman Awardon August 5, 2020 at 7:00 am
Emily Balskus has won the Alan T. Waterman Award, the National Science Foundation's most prestigious prize for scientists under 40 in the United States.
- What Doctors Really Think of Brain-Boosting Dietary Supplementson August 4, 2020 at 12:12 pm
One of the compounds found in the plant is L-DOPA, or levodopa, an amino acid that your body uses to make several neurotransmitters, including adrenaline and dopamine—which plays a role in ...
- Neuropathy in Parkinson’s Disease May Be Related to L-Dopa Exposureon August 3, 2020 at 4:59 pm
The odds ratio for exposure to L-dopa in the IPD patients with PN was 12.4 (95% confidence interval, 1.4–109.1). There were no differences between the groups in the use of other PD drugs ...
- Therapy for Dyskinesias in Parkinson's Disease Patientson August 2, 2020 at 5:00 pm
However, the severity of L-Dopa-induced dyskinesia (LID) varies between patients, being quite tolerable in late-onset patients. Understanding the pathogenesis of LID has contributed to the ...
- What Treatments Work for Parkinson’s Disease?on July 29, 2020 at 10:08 am
Doctors and patients share the treatment options for Parkinson's disease. For this Parkinson's disease guide, we interviewed seven medical experts, read numerous studies and surveyed nearly 400 people ...
- Dopamine manipulations modulate paranoid social inferences in healthy peopleon July 5, 2020 at 12:21 am
Twenty seven healthy male participants received 150mg L-DOPA, 3 mg haloperidol, or placebo in a double-blind, randomised, placebo-controlled study, over three within-subject sessions.
- New Hope for Parkinson’s Patientson June 24, 2020 at 8:34 am
Instead, in the 1960s, Arvid Carlsson found that a precursor to dopamine, called L-dopa, could cross the blood-brain barrier and help with symptoms of Parkinson’s. It’s not a perfect drug.
- Parkinson's Diseaseon February 29, 2020 at 12:02 pm
It is incorrectly believed that Parkinson's disease disappeared after the introduction of levodopa (L-dopa) in the 1960s. In fact, about 60,000 Americans are newly diagnosed with Parkinson's disease ...
- L-Dopa Capsule Side Effects by Likelihood and Severityon September 15, 2014 at 6:29 am
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except ...
- Does L-Dopa Capsule Interact with other Medications?on November 5, 2013 at 6:39 am
These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation. Selected from data included with permission and ...
via Bing News